Biogen (BIIB) Equity Average (2009 - 2026)

Biogen's Equity Average history runs 18 years deep, the most recent figure standing at $18.5 billion for Q1 2026.

• In Q1 2026, Equity Average rose 9.54% year-over-year to $18.5 billion; the TTM figure through Mar 2026 stood at $18.5 billion (up 9.54% YoY), while the FY2025 annual figure was $17.5 billion, up 10.97% from the prior year.
• Equity Average was $18.5 billion for Q1 2026 at Biogen, up from $9.2 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $18.5 billion in Q1 2026 to a low of $8.8 billion in Q3 2025.
• Historically, Equity Average has averaged $14.0 billion across 5 years, with a median of $14.5 billion in 2023.
• The sharpest annual moves came in 2023 and 2025: Equity Average rose 22.52% in 2023, then tumbled 45.16% in 2025.
• A 5-year view of Equity Average shows it stood at $13.1 billion in 2022, then grew by 11.94% to $14.6 billion in 2023, then gained by 12.96% to $16.5 billion in 2024, then sank by 44.65% to $9.2 billion in 2025, then soared by 101.59% to $18.5 billion in 2026.
• The last three Equity Average figures came in at $18.5 billion (Q1 2026), $9.2 billion (Q4 2025), and $8.8 billion (Q3 2025), per Business Quant data.